Background Standard therapy for advanced endometrial cancer after failure of platinum-based
chemotherapy remains unclear. Methods In this phase 3 trial, we randomly assigned, in a …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Simple Summary In this review, we present the latest information on the pathophysiology,
diagnosis, and local and systemic treatment of brain metastases from breast cancer, with a …

Background Most patients with ovarian cancer will relapse after receiving frontline platinum-based
chemotherapy and eventually develop platinum-resistant or platinum-refractory …

Soft tissue sarcoma (STS) is a rare tumor with more than 50 histologic subtypes. Although
treatment outcomes for patients with STS have improved greatly over the past few decades …

Background Antibody–drug conjugates have emerged as a powerful strategy in cancer therapy
and combine the ability of monoclonal antibodies to specifically target tumour cells with …

The purpose of the present study was to identify histological surrogate predictive markers of
pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-…

Background Although most patients with epithelial ovarian cancer respond to frontline
platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 JAVELIN …

Next‐generation sequencing ( NGS ) of tumor tissue (ie, clinical sequencing) can guide
clinical management by providing information about actionable gene aberrations that have …

The purpose of this study was to determine the safety, distribution, internal dosimetry, and
initial human epidermal growth factor receptor 2 (HER2)–positive tumor images of 64 Cu-…